Show simple item record

dc.contributor.authorMcDermott, D
dc.contributor.authorHaanen, J
dc.contributor.authorChen, T-T
dc.contributor.authorLorigan, Paul C
dc.contributor.authorO'Day, S
dc.date.accessioned2013-12-20T11:28:04Z
dc.date.available2013-12-20T11:28:04Z
dc.date.issued2013-10
dc.identifier.citationEfficacy and safety of Ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). 2013, 24 (10):2694-8 Ann Oncolen
dc.identifier.issn1569-8041
dc.identifier.pmid23942774
dc.identifier.doi10.1093/annonc/mdt291
dc.identifier.urihttp://hdl.handle.net/10541/308812
dc.description.abstractIn a phase III trial (ClinicalTrials.gov registration ID: NCT00094653), ipilimumab significantly improved survival versus a vaccine control in pretreated patients with metastatic melanoma. Here, we characterize outcomes of those patients who survived ≥ 2 years.
dc.language.isoenen
dc.rightsArchived with thanks to Annals of oncology : official journal of the European Society for Medical Oncology / ESMOen
dc.titleEfficacy and safety of Ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20).en
dc.typeArticleen
dc.contributor.departmentDivision of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, USA.en
dc.identifier.journalAnnals of Oncologyen
html.description.abstractIn a phase III trial (ClinicalTrials.gov registration ID: NCT00094653), ipilimumab significantly improved survival versus a vaccine control in pretreated patients with metastatic melanoma. Here, we characterize outcomes of those patients who survived ≥ 2 years.


This item appears in the following Collection(s)

Show simple item record